Roche Forecast, price target & analysts
Roche Target price 2026 - Analyst rating & recommendation
Roche Classifications & Recommendation:
Roche Price Target
| Target Price | CHF323.85 |
| Price | CHF329.90 |
| Deviation | 1.83% |
| Number of Estimates | 24 |
| 24 Analysts have issued a price target Roche 2027 . The average Roche target price is CHF323.85. This is 1.83% lower than the current stock price. The highest price target is CHF438.90 33.04% , the lowest is CHF232.30 29.58% . | |
| A rating was issued by 27 analysts: 14 Analysts recommend Roche to buy, 8 to hold and 5 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Roche stock has an average upside potential 2027 of 1.83% . Most analysts recommend the Roche stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion CHF | 60.50 | 63.00 |
| 3.03% | 4.14% | |
| EBITDA Margin | 33.78% | 39.15% |
| 5.15% | 15.88% | |
| Net Margin | 13.68% | 25.08% |
| 30.13% | 83.30% |
22 Analysts have issued a sales forecast Roche 2025 . The average Roche sales estimate is CHF63.0b . This is 2.29% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF67.6b 9.83% , the lowest is CHF59.9b 2.69% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF60.5b | 3.03% |
|---|---|---|
| 2025 | CHF63.0b | 4.14% |
| 2026 | CHF64.7b | 2.76% |
| 2027 | CHF66.7b | 3.10% |
| 2028 | CHF68.6b | 2.74% |
| 2029 | CHF72.0b | 5.05% |
| 2030 | CHF76.3b | 5.91% |
| 2031 | CHF77.8b | 1.95% |
| 2032 | CHF71.4b | 8.26% |
18 Analysts have issued an Roche EBITDA forecast 2025. The average Roche EBITDA estimate is CHF24.7b . This is 16.68% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF27.8b 31.46% , the lowest is CHF21.2b 0.29% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | CHF20.4b | 8.34% |
|---|---|---|
| 2025 | CHF24.7b | 20.69% |
| 2026 | CHF25.8b | 4.41% |
| 2027 | CHF26.8b | 4.20% |
| 2028 | CHF28.3b | 5.60% |
| 2029 | CHF30.4b | 7.43% |
| 2030 | CHF33.0b | 8.42% |
| 2031 | CHF33.9b | 2.84% |
| 2032 | CHF33.1b | 2.41% |
EBITDA Margin
| 2024 | 33.78% | 5.15% |
|---|---|---|
| 2025 | 39.15% | 15.88% |
| 2026 | 39.78% | 1.61% |
| 2027 | 40.21% | 1.08% |
| 2028 | 41.33% | 2.79% |
| 2029 | 42.27% | 2.27% |
| 2030 | 43.26% | 2.34% |
| 2031 | 43.64% | 0.88% |
| 2032 | 46.42% | 6.37% |
22 Roche Analysts have issued a net profit forecast 2025. The average Roche net profit estimate is CHF15.8b . This is 67.60% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF18.4b 94.73% , the lowest is CHF12.8b 35.40% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF8.3b | 28.01% |
|---|---|---|
| 2025 | CHF15.8b | 90.93% |
| 2026 | CHF16.6b | 4.75% |
| 2027 | CHF17.6b | 6.21% |
| 2028 | CHF18.6b | 5.91% |
| 2029 | CHF20.1b | 7.94% |
| 2030 | CHF21.7b | 8.21% |
| 2031 | CHF23.4b | 7.71% |
| 2032 | CHF24.9b | 6.26% |
Net Margin
| 2024 | 13.68% | 30.13% |
|---|---|---|
| 2025 | 25.08% | 83.30% |
| 2026 | 25.57% | 1.95% |
| 2027 | 26.34% | 3.01% |
| 2028 | 27.15% | 3.08% |
| 2029 | 27.90% | 2.76% |
| 2030 | 28.51% | 2.19% |
| 2031 | 30.12% | 5.65% |
| 2032 | 34.88% | 15.80% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 10.32 | 19.85 |
| 27.83% | 92.34% | |
| P/E | 16.62 | |
| EV/Sales | 4.46 |
22 Analysts have issued a Roche forecast for earnings per share. The average Roche EPS is CHF19.85 . This is 68.94% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF23.06 96.26% , the lowest is CHF16.03 36.43% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF10.32 | 27.83% |
|---|---|---|
| 2025 | CHF19.85 | 92.34% |
| 2026 | CHF20.79 | 4.74% |
| 2027 | CHF22.08 | 6.20% |
| 2028 | CHF23.38 | 5.89% |
| 2029 | CHF25.24 | 7.96% |
| 2030 | CHF27.31 | 8.20% |
| 2031 | CHF29.42 | 7.73% |
| 2032 | CHF31.26 | 6.25% |
P/E ratio
| Current | 28.08 | 12.92% |
|---|---|---|
| 2025 | 16.62 | 40.80% |
| 2026 | 15.87 | 4.51% |
| 2027 | 14.94 | 5.86% |
| 2028 | 14.11 | 5.56% |
| 2029 | 13.07 | 7.37% |
| 2030 | 12.08 | 7.57% |
| 2031 | 11.21 | 7.20% |
| 2032 | 10.55 | 5.89% |
Based on analysts' sales estimates for 2025, the Roche stock is valued at an EV/Sales of 4.46 and an P/S ratio of 4.13 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.56 | 22.25% |
|---|---|---|
| 2025 | 4.46 | 2.18% |
| 2026 | 4.34 | 2.69% |
| 2027 | 4.21 | 3.00% |
| 2028 | 4.10 | 2.66% |
| 2029 | 3.90 | 4.80% |
| 2030 | 3.68 | 5.59% |
| 2031 | 3.61 | 1.91% |
| 2032 | 3.94 | 9.00% |
P/S ratio
| Current | 4.22 | 22.46% |
|---|---|---|
| 2025 | 4.13 | 2.24% |
| 2026 | 4.02 | 2.69% |
| 2027 | 3.90 | 3.00% |
| 2028 | 3.79 | 2.66% |
| 2029 | 3.61 | 4.80% |
| 2030 | 3.41 | 5.58% |
| 2031 | 3.34 | 1.91% |
| 2032 | 3.64 | 9.00% |
Current Roche Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| TD COWEN |
Hold
➜
Hold
|
Unchanged | Dec 12 2025 |
| JEFFERIES |
Hold
➜
Underperform
|
Downgrade | Dec 10 2025 |
| DAY BY DAY |
Buy
➜
Buy
|
Unchanged | Dec 09 2025 |
| NYKREDIT MARKETS |
Buy
➜
Buy
|
Unchanged | Dec 05 2025 |
| BERENBERG |
Hold
➜
Hold
|
Unchanged | Dec 01 2025 |
| HSBC GLOBAL INVESTMENT RESEARCH |
Hold
➜
Buy
|
Upgrade | Nov 25 2025 |
| LANDESBANK BADEN-WUERTTEMBERG |
Buy
➜
Buy
|
Unchanged | Oct 27 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
TD COWEN:
Hold
➜
Hold
|
Dec 12 2025 |
|
Downgrade
JEFFERIES:
Hold
➜
Underperform
|
Dec 10 2025 |
|
Unchanged
DAY BY DAY:
Buy
➜
Buy
|
Dec 09 2025 |
|
Unchanged
NYKREDIT MARKETS:
Buy
➜
Buy
|
Dec 05 2025 |
|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Dec 01 2025 |
|
Upgrade
HSBC GLOBAL INVESTMENT RESEARCH:
Hold
➜
Buy
|
Nov 25 2025 |
|
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Buy
➜
Buy
|
Oct 27 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
